title: C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines.
abstract: We previously reported that fenretinide (4-HPR) was cytotoxic to acute lymphoblastic leukemia (ALL) cell lines in vitro in association with increased levels of de novo synthesized dihydroceramides, the immediate precursors of ceramides. However, the cytotoxic potentials of native dihydroceramides have not been defined. Therefore, we determined the cytotoxic effects of increasing dihydroceramide levels via de novo synthesis in T-cell ALL cell lines and whether such cytotoxicity was dependent on an absolute increase in total dihydroceramide mass versus an increase of certain specific dihydroceramides. A novel method employing supplementation of individual fatty acids, sphinganine, and the dihydroceramide desaturase-1 (DES) inhibitor, GT-11, was used to increase de novo dihydroceramide synthesis and absolute levels of specific dihydroceramides and ceramides. Sphingolipidomic analyses of four T-cell ALL cell lines revealed strong positive correlations between cytotoxicity and levels of C22:0-dihydroceramide (ρ = 0.74-0.81, P ≤ 0.04) and C24:0-dihydroceramide (ρ = 0.84-0.90, P ≤ 0.004), but not between total or other individual dihydroceramides, ceramides, or sphingoid bases or phosphorylated derivatives. Selective increase of C22:0- and C24:0-dihydroceramide increased level and flux of autophagy marker, LC3B-II, and increased DNA fragmentation (TUNEL assay) in the absence of an increase of reactive oxygen species; pan-caspase inhibition blocked DNA fragmentation but not cell death. C22:0-fatty acid supplemented to 4-HPR treated cells further increased C22:0-dihydroceramide levels (P ≤ 0.001) and cytotoxicity (P ≤ 0.001). These data demonstrate that increases of specific dihydroceramides are cytotoxic to T-cell ALL cells by a caspase-independent, mixed cell death mechanism associated with increased autophagy and suggest that dihydroceramides may contribute to 4-HPR-induced cytotoxicity. The targeted increase of specific acyl chain dihydroceramides may constitute a novel anticancer approach.
authors.affiliation: School of Medicine Cancer Center, Texas Tech University Health Sciences Center, Lubbock, Texas, United States of America.
authors.forename: Michael W
authors.initials: MW
authors.lastname: Holliday
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Cox
authors.forename: Min H
authors.initials: MH
authors.lastname: Kang
authors.forename: Barry J
authors.initials: BJ
authors.lastname: Maurer
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry; D001343:Autophagy; D045744:Cell Line, Tumor; D002518:Ceramides / Q000737:chemistry*; D003470:Culture Media / Q000737:chemistry; D053938:DNA Fragmentation; D005227:Fatty Acids / Q000737:chemistry; D006801:Humans; D008928:Mitochondria / Q000378:metabolism; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism*; D017382:Reactive Oxygen Species; D013107:Sphingolipids / Q000737:chemistry; D013110:Sphingosine / Q000031:analogs & derivatives / Q000737:chemistry
chemical_list: D000970:Antineoplastic Agents; D002518:Ceramides; D003470:Culture Media; D005227:Fatty Acids; D017382:Reactive Oxygen Species; D013107:Sphingolipids; C109343:dihydroceramide; D013110:Sphingosine; C005682:safingol
references.citation: J Lipid Res. 1983 May;24(5):662-5
references.pmid: 6875391
references.citation: J Biol Chem. 2010 Sep 17;285(38):29078-90
references.pmid: 20628055
references.citation: Br J Dermatol. 2000 Dec;143(6):1154-63
references.pmid: 11122015
references.citation: J Biol Chem. 2011 Jul 15;286(28):24754-64
references.pmid: 21543327
references.citation: Mol Cancer Ther. 2008 Sep;7(9):2967-76
references.pmid: 18790777
references.citation: Clin Cancer Res. 2007 May 15;13(10):3079-86
references.pmid: 17505011
references.citation: J Natl Cancer Inst. 2008 Apr 16;100(8):580-95
references.pmid: 18398104
references.citation: Bioorg Med Chem. 2003 Jul 3;11(13):2723-8
references.pmid: 12788346
references.citation: Leukemia. 2008 Jun;22(6):1258-62
references.pmid: 18033322
references.citation: Can J Biochem Physiol. 1959 Aug;37(8):911-7
references.pmid: 13671378
references.citation: J Biol Chem. 2008 Feb 29;283(9):5677-84
references.pmid: 18165233
references.citation: Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1293-301
references.pmid: 11142414
references.citation: Cancer Lett. 2004 Apr 8;206(2):169-80
references.pmid: 15013522
references.citation: FEBS Lett. 2010 May 3;584(9):1907-13
references.pmid: 20035755
references.citation: Cancer Lett. 2009 Sep 18;282(2):238-43
references.pmid: 19394759
references.citation: J Org Chem. 2003 Dec 26;68(26):9924-32
references.pmid: 14682684
references.citation: Cancer Res. 2001 Jul 1;61(13):5102-5
references.pmid: 11431347
references.citation: Biochem Cell Biol. 2012 Apr;90(2):209-23
references.pmid: 22428532
references.citation: J Biol Chem. 2007 Jun 8;282(23):16718-28
references.pmid: 17283068
references.citation: Br J Cancer. 2009 Feb 24;100(4):626-32
references.pmid: 19223911
references.citation: J Natl Cancer Inst. 2000 Dec 6;92(23):1897-909
references.pmid: 11106681
references.citation: J Natl Cancer Inst. 1997 Aug 20;89(16):1191-8
references.pmid: 9274913
references.citation: IUBMB Life. 2010 May;62(5):347-56
references.pmid: 20222015
references.citation: Biochim Biophys Acta. 1988 Mar 25;959(2):185-96
references.pmid: 3349097
references.citation: Exp Biol Med (Maywood). 2002 May;227(5):345-53
references.pmid: 11976405
references.citation: Adv Exp Med Biol. 2010;688:1-23
references.pmid: 20919643
references.citation: Nat Rev Cancer. 2004 Aug;4(8):604-16
references.pmid: 15286740
references.citation: Cancer Res. 1999 May 15;59(10):2493-8
references.pmid: 10344763
references.citation: Leuk Res. 2003 Mar;27(3):259-66
references.pmid: 12537979
references.citation: J Biol Chem. 1997 Sep 5;272(36):22432-7
references.pmid: 9312549
references.citation: J Biol Chem. 2006 Feb 3;281(5):2784-94
references.pmid: 16303764
references.citation: Cell Metab. 2007 Mar;5(3):167-79
references.pmid: 17339025
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: J Natl Cancer Inst. 1999 Jul 7;91(13):1138-46
references.pmid: 10393722
references.citation: Int J Cancer. 2012 Feb 1;130(3):685-93
references.pmid: 21400505
references.citation: Anticancer Res. 2011 Mar;31(3):961-6
references.pmid: 21498721
references.citation: Mol Cancer Ther. 2007 Mar;6(3):886-97
references.pmid: 17363483
references.citation: Prog Lipid Res. 2012 Apr;51(2):82-94
references.pmid: 22200621
references.citation: Methods. 2006 Jun;39(2):82-91
references.pmid: 16828308
references.citation: FEBS Lett. 2007 Nov 13;581(27):5289-94
references.pmid: 17977534
references.citation: Biochim Biophys Acta. 2006 Dec;1758(12):1864-84
references.pmid: 17052686
references.citation: J Biol Chem. 2011 Nov 4;286(44):38069-38078
references.pmid: 21914808
references.citation: Cancer Res. 1993 Dec 15;53(24):6036-41
references.pmid: 8261419
references.citation: J Biol Chem. 1999 Mar 5;274(10):6080-4
references.pmid: 10037689
references.citation: J Biol Chem. 1993 Dec 15;268(35):26226-32
references.pmid: 8253743
references.citation: Carcinogenesis. 1997 May;18(5):943-8
references.pmid: 9163679
references.citation: Leukemia. 2002 May;16(5):902-10
references.pmid: 11986953